騰盛博藥(02137.HK):收到美衛生研究院ACTIV-2三期臨牀試驗結果
騰盛博藥(02137.HK)公佈,已收到由美國國立衛生研究院支持的ACTIV-2三期臨牀試驗分析、基於患者總人數的關鍵性數據分析結果。結果顯示,公司在研的新型冠狀病毒聯合療法(即安巴韋單抗/羅米司韋單抗聯合療法,在疾病進展高風險的門診患者中,住院及死亡的複合終點降低80%,治療組受試者在28天治療期內無死亡,而安慰劑組有9例死亡。
相較安慰劑組,安巴韋單抗/羅米司韋單抗聯合療法治療組的3級或以上不良事件較不常見,且未發現與藥物相關的嚴重不良事件或輸液反應。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.